Quest Diagnostics is positioned for growth driven by advanced diagnostics and operational improvements, though debt and macroeconomic pressures remain concerns. The company saw high single-digit growth in physician channel revenues in the first quarter of 2026, supported by strong demand for innovative testing and expanded health plan access. Its AD-Detect blood test for Alzheimer's disease continued double-digit revenue growth, and the company is scaling its Co-Lab Solutions across all 21 hospitals of Corewell Health. However, long-term debt stood at $5.16 billion against a cash balance of only $393 million, with a debt-to-capital ratio of 42.5%. The Zacks Consensus Estimate for 2026 earnings per share is $10.72 on revenues of $11.83 billion, implying 7.2% growth.
Quest Diagnostics IncorporatedStrong demand for advanced diagnostics, including AD-Detect Alzheimer's test and Co-Lab Solutions expansion, driving revenue growth
Integra LifeSciences Holdings
Align Technology Inc
Globus Medical